Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563610 | 0.86 | LMNA (0.36) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL9136144 | 0.84 | KCNH2 (0.49) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL10494760 | 0.81 | KCNH2 (0.49) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL6563477 | 0.80 | MEN1 (0.40) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL438993 | 0.80 | KCNH2 (0.44) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL14598859 | 0.80 | KCNH2 (0.44) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL405660 | 0.80 | KCNH2 (0.44) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL6527472 | 0.79 | KCNH2 (0.47) | KCNH2MEN1KMT2ANPC1TP53 | |
| SCHEMBL28728445 | 0.78 | KCNH2 (0.45) | KCNH2MEN1KMT2ANPC1TP53 | |
| Trifluoroacetic Acid SCHEMBL7806342 | 0.78 | KCNH2 (0.40) | KCNH2MEN1KMT2ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397339-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-10-16 | — | — | US | disclosed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | PGD, AADAT, TRHDE | KCNH2 4615/4885MEN1 439/4885KMT2A 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.